Chengdu SBK Wins 2024 ‘Golden Panda Future Star’ Enterprise Award

On May 15, 2024, the launch ceremony for the Digital Discovery and Cultivation Platform of Leading Technologies for Sci-Tech Enterprises and the “Golden Panda Future Star • Enterprise Benefit Tour” was successfully held in Chengdu Hi-Tech Zone. The event was guided by the Chengdu Science and Technology Bureau and the Chengdu Hi-Tech Industrial Development Zone Technology Innovation Bureau, and hosted by Chengdu Prism Digital Technology Co., Ltd. and CDHT Investment Winpower Investment Development Co., Ltd.

Chengdu SBK Biomedical Technology Co., Ltd. was honored as a 2024 “Golden Panda Future Star” enterprise for its innovative work in “Integrated Innovative Technology for Drug Metabolism Differentiation”. This recognition highlights the company’s strong innovation capabilities and serves as a great motivation for further development and progress.

The “Golden Panda Future Star Platform” uses digital and AI tools to evaluate companies across six key dimensions and 21 indicators, including technical expertise, corporate strength, team capabilities, market competitiveness, and leadership vision. Out of over 230,000 enterprises in the High-Tech Zone, 284 “Golden Panda Future Star” enterprises with “core critical technologies” were selected. Among these, 61 were in the pharmaceutical and health (innovative drug) sector, making up 21.48% of the total. All selected enterprises share common traits, such as the ability to create high-quality productive forces, possess top-tier teams, demonstrate strong innovative capabilities, and attract significant capital investment.

About SBK
Headquartered in the Chengdu Hi-Tech Industrial Development Zone, Chengdu Shibeikang Biomedical Technology Co., Ltd. is a research-driven company rooted in China, serving the world and dedicated to differentiated drug innovation. We are dedicated to becoming a world leader in the differentiated innovation of novel drugs with a focus on cardiovascular, cerebrovascular, and respiratory therapies. We have built an integrated innovation platform centered on drug metabolism differentiation, supported by 51 proprietary intellectual properties. This platform enables the identification of drugs with metabolic deficiencies and the design of novel molecular structures to address clinical challenges related to metabolic variability—such as individual differences in drug safety and efficacy—ultimately meeting the pressing therapeutic needs of patients.

Looking ahead, we will continue to harness our integrated innovation platform for drug metabolism differentiation to drive technological breakthroughs and develop superior novel therapies that advance global health.